1. Home
  2. PRFX vs ARTL Comparison

PRFX vs ARTL Comparison

Compare PRFX & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$0.89

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.54

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRFX
ARTL
Founded
2007
2011
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
2.6M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PRFX
ARTL
Price
$0.89
$1.54
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$30.00
AVG Volume (30 Days)
95.3K
108.0K
Earning Date
02-27-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$1.15
52 Week High
$6.65
$28.60

Technical Indicators

Market Signals
Indicator
PRFX
ARTL
Relative Strength Index (RSI) 49.84 43.07
Support Level $0.66 $1.48
Resistance Level $0.74 $1.82
Average True Range (ATR) 0.06 0.16
MACD 0.01 0.04
Stochastic Oscillator 74.46 50.75

Price Performance

Historical Comparison
PRFX
ARTL

About PRFX PainReform Ltd.

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: